Sponsored by the North American Center for Continuing Medical Education (NACCME)

Target Audience

This activity is designed for Dermatologists.

Learning Objectives

After completing this activity, participants should be able to:

• discuss the efficacy of topical corticosteroids in treating atopic dermatitis
• review potential side effects such as telangiectasia and hypopigmentation that may occur with the use of topical corticosteroids
• assess the role of emollients in treating atopic dermatitis
• discuss the pros and cons of topical calcineurin inhibitors such as tacrolimus ointment and pimecrolimus cream
• determine the role of topical and/or oral antibiotics within the armamentarium of modalities for atopic dermatitis
• discuss indications for phototherapy in patients with atopic dermatitis
• review recent studies on the use of combination therapy in managing atopic dermatitis
• discuss recent studies on emerging agents that may have potential in treating moderate to severe atopic dermatitis 

Credit Eligibility/Method of Participation

To be eligible for documentation of credit, participants must participate in the webcast complete the post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Please e-mail info@naccme.com or call 609-371-1137 if you have questions or need additional information.

Release Date: 12/16/08

Expiration Date: 12/16/09

Estimated time to complete activity: 1 hour

There is no fee for participation associated with this activity.

CME Accrediation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NACCME designates this educational activity for a maximum of  1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CPME Accrediation

NACCME is approved by the Council on Podiatric Medical Education as a sponsor of continuing education in podiatric medicine. This program is approved for 1 continuing education contact hours.

Grant Support

Supported by an educational grant from Astellas Pharmaceuticals

Presenters/Faculty

Lawrence Eichenfield, M.D.
Chief, Pediatric and Adolescent Dermatology
Professor of Pediatrics and Medicine (Dermatology)
Rady Children's Hospital, San Diego
University of California, San Diego School of Medicine
San Diego, California

Alan B. Fleischer, Jr., M.D.
Professor and Chair of Dermatology
Wake Forest University Health Sciences
Winston-Salem North Carolina

Independent Clinical Reviewer

Bobby Buka, MD
Section Chief, Dept. of Dermatology
Mount Sinai School of Medicine
New York, New York

Planning Committee Lawrence Eichenfield, M.D, Alan B. Fleischer, Jr., M.D., T. Levy, NACCME and J. Hall, HMP Communications.

Financial Disclosure and Conflicts of Interest Policy

According to the disclosure policy of NACCME, all faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME, LLC to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty have reported the following

Dr. Eichenfield has disclosed that he has received grant/research support from Astellas, Novartis, SkinMedica and Stiefel.

Dr. Fleischer has disclosed that he has received grant/research support from 3M, Abbott, Amgen, Astellas, Asubio, Biogen, Dow, Centocor, Coria, Galderma, GSK, Genentech, Healthpoint, Intendis, Medicis, Novartis, Ortho-Neutrogena, Pfizer and Stiefel. He is a consultant to Astellas, Asubio, Combe, Galderma, Gerson Lehrman, Intendis, Kikaku America International, Merz, Novartis, and Serentis. He is a scientific advisor for Allergan, Amgen, Astellas, Galderma, GSK, Ortho-Neutrogena, and Stiefel. He is a member of the speakers’ bureau for Amgen, Astellas, Galderma, Intendis, Medicis, Novartis and Stiefel. 

Independent Clinical Reviewer: B. Buka, M.D. has disclosed that he has no relevant financial relationships with any commercial interest

Planning Committee T. Levy and J. Hall have disclosed that they have no relevant financial relationship with any commercial interest.

Off label/unapproved use statement and disclosure

NACCME, LLC requires faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.

The faculty has disclosed that off-label/unapproved use of multiple topical corticosteroids for the treatment of atopic dermatitis will be discussed.

Privacy Policy

NACCME, LLC protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME, LLC and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME, LLC maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2008 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the North American Center for Continuing Medical Education.